Core Points - The Consumers Energy Foundation announced the 2024 Prosperity Award Winners, granting $250,000 each to West Branch and Mundy Township for community projects [1][3] - The Prosperity Awards aim to support economic development and enhance community welfare through strategic investments [2][4] Group 1: Grant Recipients - City of West Branch will use the grant to construct the "Gathering Place," a park designed to foster social interactions and cultural activities in downtown [2][3] - Mundy Township will utilize the funding for an accessible amphitheater stage at Mundy Miracle Commons Park, enhancing entertainment options for all abilities [2][3] Group 2: Foundation Overview - The Consumers Energy Foundation is the charitable arm of Consumers Energy, focusing on community growth and prosperity in Michigan [4] - In 2023, the Foundation and its affiliates contributed over $11 million to Michigan nonprofits, demonstrating a commitment to local development [4] Group 3: Total Funding - The Prosperity Awards represent the final signature grant allocations for 2024, totaling $1.5 million, following previous awards in April and July [3]

-- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- -- National Reimbursement Payment Determination from CMS for its PoNS Controller Deferred to the Next Cycle -- NEWTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced t ...

JACKSON, Mich., Oct. 10, 2024 /PRNewswire/ -- CMS Energy announced today it will provide 2024 third quarter results along with a business and financial outlook at 9:30 a.m. EDT on Thursday, October 31, 2024. A webcast of the presentation will be available on CMS Energy's website, cmsenergy.com. An audio replay will be available approximately three hours after the webcast and will be archived for 30 days on CMS Energy's website in the "Investor Relations" section. CMS Energy (NYSE: CMS) is a Michigan-based e ...

Core Insights - HeartCore Enterprises, Inc. has achieved the top market share in sales value for its Content Management System (CMS) in Japan for nine consecutive years, holding a 15.1% market share compared to the second contender at 12.5% [1][2] - Over 700 Japanese companies have adopted HeartCore's CMS, reflecting strong confidence in the platform [2][3] - The company has reported two consecutive quarters of profitable performance in its software division, driven by proactive cost reduction initiatives and sales growth [2][3] Company Developments - HeartCore launched a Management Screen Builder feature in December, enhancing website operation capabilities and driving innovation [3] - The acquisition of Sigmaways and Sabatini Global last year has positively impacted HeartCore's growth, with a focus on exploring additional synergistic opportunities for global market expansion [3] - HeartCore offers a range of services including Software as a Service (SaaS) solutions, data analytics, customer experience management, and digital transformation services [4]

Core Insights - Akebia Therapeutics announced that its product Vafseo (vadadustat) has been approved for the Transitional Drug Add-On Payment Adjustment (TDAPA) by the Center for Medicare & Medicaid Services (CMS), effective January 1, 2025, providing two years of reimbursement in addition to the ESRD bundled rate for dialysis organizations [1][2][3] Group 1: Product and Approval Details - Vafseo is indicated for the treatment of anemia due to chronic kidney disease in adults who have been on dialysis for at least three months and was approved by the FDA in March 2024 [1][5][6] - A Level II Healthcare Common Procedure Coding System (HCPCS) code has been assigned to Vafseo to facilitate billing for Medicare enrollees [2][3] - The product is expected to be available in the market starting January 2025 [1][3] Group 2: Commercial Strategy and Engagement - Akebia is actively engaging with dialysis organizations to facilitate access to Vafseo and plans to interact with nephrologists and healthcare providers at the upcoming American Society of Nephrology conference [3] - The TDAPA status and billing code are seen as significant milestones in the commercial launch of Vafseo, aimed at driving usage and demand [3] Group 3: Company Overview - Akebia Therapeutics, founded in 2007 and headquartered in Cambridge, Massachusetts, focuses on improving the lives of individuals affected by kidney disease [4]

NEW YORK and TOKYO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) ("HeartCore" or "the Company"), a leading enterprise software and data consulting services company based in Tokyo, announced it has been awarded a new contract from Fourmix Co., Ltd. ("Fourmix"), a Japanese IT and web development company. Partnership Logo Through this contract, HeartCore will implement its CMS platform to enhance Fourmix's web development and digital marketing domain capabilities. HeartCore will ...

Core Viewpoint - CMS Energy Corporation is systematically investing in operations to enhance service quality and expand its renewable energy portfolio while phasing out coal generation [1] Group 1: Investment and Growth Plans - CMS Energy plans to invest $17 billion in capital expenditures from 2024 to 2028 to renovate infrastructure and boost clean power production [2] - The company aims to install approximately 8,000 MW of solar production by 2040 and will begin deploying battery storage, targeting 75 MW by 2027 and an additional 475 MW by 2040 [3] - An 85-megawatt solar array is planned at the former D.E. Karn coal-generating plant, expected to be operational by 2026, which will diversify the renewable energy portfolio [3] Group 2: Operational Resilience and Cost Management - CMS Energy is focusing on enhancing grid resilience to reduce outages and protect infrastructure from extreme weather, which will lower operating costs and increase revenue [4] - The company is expected to incur $238 million in costs between 2024 and 2028 to comply with environmental regulations regarding coal ash disposal [5] Group 3: Market Performance - Over the past three months, CMS Energy's stock has increased by 18.8%, outperforming the industry growth of 12.8% [7]

TI AND FOR 1 11:10 THE HD imantsu With the recent rise in the utility segment valuations as investors prepare for the strong potential of lower competitive interest rates, CMS Energy Co (NYSE:CMS) stock price has been strong. This has led to an overabundance of "Hold" recommendations for CMS stock. However, for long-term investors, CMS should be viewed as a highquality selection, both in earnings and dividend production and, more importantly, in its supportive regulatory background. I do not own the common ...

Core Insights - Abeona Therapeutics announced that the Centers for Medicare and Medicaid Services (CMS) has granted a product-specific procedure code ICD-10-PCS for prademagene zamikeracel (pz-cel), an investigational gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) [1] - CMS assigned Medicare reimbursement for pz-cel to Pre-Major Diagnostic Category, Medicare Severity Diagnosis Related Group 018, which is among the highest reimbursement levels for cell and gene therapies, effective October 1, 2024 [2] - The Chief Commercial Officer of Abeona expressed confidence in securing access and reimbursement for RDEB patients following favorable Medicare decisions and positive feedback from commercial payers [3] Product Overview - Prademagene zamikeracel (pz-cel) is an autologous cell-based gene therapy designed to treat RDEB, a rare connective tissue disorder caused by a defect in the COL7A1 gene [4] - Pz-cel aims to incorporate the functional COL7A1 gene into a patient's skin cells, enabling long-term gene expression and facilitating wound healing [4] - The pivotal Phase 3 VIITAL™ study evaluated pz-cel's efficacy, safety, and tolerability in 43 large chronic wound pairs among 11 subjects with RDEB [4] Company Background - Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases [5] - The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which supports the production of pz-cel for clinical trials and potential commercial use [5] - Abeona's development portfolio includes AAV-based gene therapies for ophthalmic diseases, utilizing next-generation AAV capsids to improve treatment efficacy [5]

Multiple AI-powered features and seamless CMS integration influence Sitefinity Insight's status as a RealCDP™ BURLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Progress (Nasdaq: PRGS), the trusted provider of AI-powered infrastructure software, today announced that Progress® Sitefinity Insight® customer data platform (CDP) has been certified by the Customer Data Platform (CDP) Institute as a RealCDP™ for meeting specific standards and capabilities that are essential for managing and utilizing customer da ...